Dengue Fever Research Today is a free monthly online journal that collates and summarizes the latest research about Dengue Fever, including details on symptoms, risk factors, diagnosis, treatment, prevention.

The epidemiology of dengue in the americas over the last three decades: a worrisome reality.

San Martín JL, Brathwaite O, Zambrano B, Solórzano JO, Bouckenooghe A, Dayan GH, Guzmán MG

Dengue Regional Program, Pan American Health Organization (PAHO), Panama, Republic of Panama. sanmarjl@pan.ops-oms.org

We have reported the epidemic patterns of dengue disease in the Region of the Americas from 1980 through 2007. Dengue cases reported to the Pan American Health Organization were analyzed from three periods: 1980-1989 (80s), 1990-1999 (90s), and 2000-2007 (2000-7). Age distribution data were examined from Brazil, Venezuela, Honduras, and Mexico. Cases increased over time: 1,033,417 (80s) to 2,725,405 (90s) to 4,759,007 (2000-7). The highest concentrations were reported in the Hispanic Caribbean (39.1%) in the 80s shifting to the Southern Cone in the 90s (55%) and 2000-7 (62.9%). From 1980 through 1987, 242 deaths were reported compared with 1,391 during 2000-7. The most frequently isolated serotypes were DENV-1 and DENV-2 (90s) and DENV-2 and DENV-3 (2000-7). The highest incidence was observed among adolescents and young adults; dengue hemorrhagic fever incidence was highest among infants in Venezuela. Increasing dengue morbidity/mortality was observed in the Americas in recent decades.

Published 12 January 2010 in Am J Trop Med Hyg, 82(1): 128-35.
Full-text of this article is available online (may require subscription).

Articles on Dengue Fever published 11 January 2010:

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.   J Infect Dis, 201(3): 370-7.

BACKGROUND. Sanofi Pasteur has developed a tetravalent dengue vaccine (TDV) against the world's most common arbovirus infection. METHODS. We assessed the safety and immunogenicity of the TDV in healthy adults randomized into 2 groups. Group 1 received 3 TDV injections at months 0, 4, and 12-15; group 2 received saline placebo at month 0 and then 2 TDV injections at months 4 and 12-15. Adverse events were recorded, and biological parameters and viremia levels were measured. Neutralizing ... [Abstract] [Full-text]

Articles on Dengue Fever published 5 January 2010:

Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection.   FASEB J, 24(1): 218-28.

Dengue fever is an emerging viral disease transmitted by arthropods to humans in tropical countries. Dengue hemorrhagic fever (DHF) is escalating in frequency and mortality rates. Here we studied the involvement of macrophage migration inhibitory factor (MIF) in dengue virus (DENV) infection and its pathogenesis. Patients with DHF had elevated plasma concentrations of MIF. Both leukocytes from these patients and macrophages from healthy donors infected in vitro with DENV showed a substantial ... [Abstract] [Full-text]

Articles on Dengue Fever published 9 December 2009:

Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua.   J Infect Dis, 201(1): 5-14.

BACKGROUND: Dengue is the most prevalent mosquito-borne viral disease in humans and a major urban public health problem worldwide. METHODS: A prospective cohort study of approximately 3800 children initially aged 2-9 years was established in Managua, Nicaragua, in 2004 to study the natural history of dengue transmission in an urban pediatric population. Blood samples from healthy subjects were collected annually prior to the dengue season, and identification of dengue cases occurred via ... [Abstract] [Full-text]

Articles on Dengue Fever published 7 December 2009:

Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.   Virology, 396(2): 280-8.

A new vaccination strategy for dengue virus (DENV) was evaluated in rhesus macaques by priming with tetravalent purified inactivated virus (TPIV) or tetravalent plasmid DNA vaccines expressing the structural prME gene region (TDNA) then boosting 2 months later with a tetravalent live attenuated virus (TLAV) vaccine. Both vaccine combinations elicited virus neutralizing (N) antibodies. The TPIV/TLAV combination afforded complete protection against DENV 3 challenge at month 8. In a second ... [Abstract] [Full-text]

Articles on Dengue Fever published 30 November 2009:

JNK phosphorylation, induced during dengue virus infection, is important for viral infection and requires the presence of cholesterol.   Virology, 396(1): 30-6.

Infection with a broad diversity of viruses often activates host cell signaling pathways including the mitogen-activated protein kinase pathway. The present study established that dengue virus infection of human macrophages activates Jun NH(2)-terminal kinase (JNK) and the p38 MAPKs pathways. The activation was observed at early times after infection and occurs when either infectious or UV-inactivated dengue virus was used. The role of these activated kinases in dengue virus infection was ... [Abstract] [Full-text]

Articles on Dengue Fever published 25 November 2009:

Comparison of prevalence of dengue maculopathy during two epidemics with differing predominant serotypes.   Am J Ophthalmol, 148(6): 910-3.

PURPOSE: To compare the prevalence of dengue maculopathy among patients hospitalized for dengue fever during a 2007 epidemic with its prevalence during the 2005 epidemic. DESIGN: Cross-sectional observational study of consecutive patients hospitalized in two general hospitals with dengue fever during the dengue epidemic. METHODS: A standard questionnaire on ocular history and symptoms was completed by all patients. Their near and distance vision, Amsler grid test results, and dilated fundal ... [Abstract] [Full-text]

Articles on Dengue Fever published 20 November 2009:

Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants.   J Infect Dis, 200(12): 1893-900.

Dengue hemorrhagic fever can occur in primary dengue virus (DENV) infection of infants. The decay of maternally derived DENV immunoglobulin (Ig) G and the incidence of DENV infection were determined in a prospectively studied cohort of 1244 Vietnamese infants. Higher concentrations of total IgG and DENV-reactive IgG were found in cord plasma relative to maternal plasma. Maternally derived DENV-neutralizing and E protein-reactive IgG titers declined to below measurable levels in >90% of ... [Abstract] [Full-text]

Dengue virus infection induces upregulation of GRP78, which acts to chaperone viral antigen production.   J Virol, 83(24): 12871-80.

Dengue virus (DENV) pathogenesis is related to the host responses to viral infection within target cells, and therefore, this study assessed intracellular changes in host proteins following DENV infection. Two-dimensional gel electrophoresis and mass spectrometry identified upregulation of the host endoplasmic reticulum (ER) chaperone GRP78 in K562 cells following DENV infection, in the absence of virus-induced cell death. Upregulation of GRP78 in DENV-infected cells was confirmed by ... [Abstract] [Full-text]

© 2004-2010 Dengue Fever Research Today. All Rights Reserved.